# Innospec Inc.: financial statements, quarterly

IOSP · Nasdaq · CIK 1054905 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/iosp.md) · [Financials](/companies/iosp/financials.md) · [Filings](/companies/iosp/filings.md) · [Insiders](/companies/iosp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/iosp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [464](/filings/0000950170-24-121901.md) | [495 d](/filings/0001193125-26-056502.md) | [500](/filings/0000950170-25-067608.md) | [435](/filings/0000950170-25-103628.md) | [443](/filings/0001193125-25-266077.md) | [467 d](/filings/0001193125-26-056502.md) | [441](/filings/0001193125-26-213510.md) | [440](/filings/0001193125-26-334178.md) | [442](/filings/0001193125-25-266077.md) | [456 d](/filings/0001193125-26-056502.md) | [453](/filings/0001193125-26-213510.md) | [491](/filings/0001193125-26-334178.md) |
| Cost of revenue | $m | [327](/filings/0000950170-24-121901.md) | [339 d](/filings/0001193125-26-056502.md) | [345](/filings/0000950170-25-067608.md) | [308](/filings/0000950170-25-103628.md) | [319](/filings/0001193125-25-266077.md) | [331 d](/filings/0001193125-26-056502.md) | [316](/filings/0001193125-26-213510.md) | [317](/filings/0001193125-26-334178.md) | [325](/filings/0001193125-25-266077.md) | [328 d](/filings/0001193125-26-056502.md) | [330](/filings/0001193125-26-213510.md) | [353](/filings/0001193125-26-334178.md) |
| Gross profit | $m | [137](/filings/0000950170-24-121901.md) | [156 d](/filings/0001193125-26-056502.md) | [156](/filings/0000950170-25-067608.md) | [127](/filings/0000950170-25-103628.md) | [124](/filings/0001193125-25-266077.md) | [136 d](/filings/0001193125-26-056502.md) | [125](/filings/0001193125-26-213510.md) | [123](/filings/0001193125-26-334178.md) | [117](/filings/0001193125-25-266077.md) | [127 d](/filings/0001193125-26-056502.md) | [124](/filings/0001193125-26-213510.md) | [138](/filings/0001193125-26-334178.md) |
| Research and development | $m | [11.6](/filings/0000950170-24-121901.md) | [16.2 d](/filings/0001193125-26-056502.md) | [14.0](/filings/0000950170-25-067608.md) | [14.0](/filings/0000950170-25-103628.md) | [13.6](/filings/0001193125-25-266077.md) | [14.9 d](/filings/0001193125-26-056502.md) | [12.7](/filings/0001193125-26-213510.md) | [13.6](/filings/0001193125-26-334178.md) | [13.7](/filings/0001193125-25-266077.md) | [11.0 d](/filings/0001193125-26-056502.md) | [13.2](/filings/0001193125-26-213510.md) | [14.2](/filings/0001193125-26-334178.md) |
| Selling, general and administrative | $m | [83.7](/filings/0000950170-24-121901.md) | [95.0 d](/filings/0001193125-26-056502.md) | [90.5](/filings/0000950170-25-067608.md) | [71.6](/filings/0000950170-25-103628.md) | [64.3](/filings/0001193125-25-266077.md) | [78.9 d](/filings/0001193125-26-056502.md) | [69.3](/filings/0001193125-26-213510.md) | [74.6](/filings/0001193125-26-334178.md) | [71.9](/filings/0001193125-25-266077.md) | [69.3 d](/filings/0001193125-26-056502.md) | [78.5](/filings/0001193125-26-213510.md) | [84.3](/filings/0001193125-26-334178.md) |
| Operating income | $m | [41.9](/filings/0000950170-24-121901.md) | [44.5 d](/filings/0001193125-26-056502.md) | [50.5](/filings/0000950170-25-067608.md) | [40.7](/filings/0000950170-25-103628.md) | [45.6](/filings/0001193125-25-266077.md) | [41.1 d](/filings/0001193125-26-056502.md) | [42.5](/filings/0001193125-26-213510.md) | [34.3](/filings/0001193125-26-334178.md) | [5.9](/filings/0001193125-25-266077.md) | [46.8 d](/filings/0001193125-26-056502.md) | [36.5](/filings/0001193125-26-213510.md) | [39.7](/filings/0001193125-26-334178.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [8.3](/filings/0000950170-24-121901.md) | [7.5 d](/filings/0001193125-26-056502.md) | [13.9](/filings/0000950170-25-067608.md) | [12.5](/filings/0000950170-25-103628.md) | [11.4](/filings/0001193125-25-266077.md) | [(32.2) d](/filings/0001193125-26-056502.md) | [11.6](/filings/0001193125-26-213510.md) | [8.4](/filings/0001193125-26-334178.md) | [(1.4)](/filings/0001193125-25-266077.md) | [2.9 d](/filings/0001193125-26-056502.md) | [9.1](/filings/0001193125-26-213510.md) | [10.4](/filings/0001193125-26-334178.md) |
| Net income | $m | [39.2](/filings/0000950170-24-121901.md) | [37.8 d](/filings/0001193125-26-056502.md) | [41.4](/filings/0000950170-25-067608.md) | [31.2](/filings/0000950170-25-103628.md) | [33.4](/filings/0001193125-25-266077.md) | [(70.4) d](/filings/0001193125-26-056502.md) | [32.8](/filings/0001193125-26-213510.md) | [23.5](/filings/0001193125-26-334178.md) | [12.9](/filings/0001193125-25-266077.md) | [47.4 d](/filings/0001193125-26-056502.md) | [30.4](/filings/0001193125-26-213510.md) | [30.8](/filings/0001193125-26-334178.md) |
| Diluted EPS | $ per share | [1.57](/filings/0000950170-24-121901.md) | not reported | [1.65](/filings/0000950170-25-067608.md) | [1.24](/filings/0000950170-25-103628.md) | [1.33](/filings/0001193125-25-266077.md) | not reported | [1.31](/filings/0001193125-26-213510.md) | [0.94](/filings/0001193125-26-334178.md) | [0.52](/filings/0001193125-25-266077.md) | not reported | [1.22](/filings/0001193125-26-213510.md) | [1.25](/filings/0001193125-26-334178.md) |
| Basic EPS | $ per share | [1.58](/filings/0000950170-24-121901.md) | not reported | [1.66](/filings/0000950170-25-067608.md) | [1.25](/filings/0000950170-25-103628.md) | [1.34](/filings/0001193125-25-266077.md) | not reported | [1.31](/filings/0001193125-26-213510.md) | [0.94](/filings/0001193125-26-334178.md) | [0.52](/filings/0001193125-25-266077.md) | not reported | [1.23](/filings/0001193125-26-213510.md) | [1.25](/filings/0001193125-26-334178.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss, us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [207](/filings/0000950170-23-060765.md) | [204](/filings/0000950170-25-022803.md) | [270](/filings/0000950170-24-057487.md) | [240](/filings/0000950170-24-092351.md) | [304](/filings/0000950170-24-121901.md) | [289](/filings/0001193125-26-056502.md) | [300](/filings/0000950170-25-067608.md) | [267](/filings/0000950170-25-103628.md) | [271](/filings/0001193125-25-266077.md) | [293](/filings/0001193125-26-334178.md) | [289](/filings/0001193125-26-213510.md) | [250](/filings/0001193125-26-334178.md) |
| Current assets | $m | [864](/filings/0000950170-23-060765.md) | [886](/filings/0000950170-25-022803.md) | [913](/filings/0000950170-24-057487.md) | [877](/filings/0000950170-24-092351.md) | [966](/filings/0000950170-24-121901.md) | [957](/filings/0001193125-26-056502.md) | [977](/filings/0000950170-25-067608.md) | [970](/filings/0000950170-25-103628.md) | [989](/filings/0001193125-25-266077.md) | [1,005](/filings/0001193125-26-334178.md) | [999](/filings/0001193125-26-213510.md) | [1,025](/filings/0001193125-26-334178.md) |
| Total assets | $m | [1,619](/filings/0000950170-23-060765.md) | [1,707](/filings/0000950170-25-022803.md) | [1,733](/filings/0000950170-24-057487.md) | [1,700](/filings/0000950170-24-092351.md) | [1,798](/filings/0000950170-24-121901.md) | [1,735](/filings/0001193125-26-056502.md) | [1,775](/filings/0000950170-25-067608.md) | [1,806](/filings/0000950170-25-103628.md) | [1,799](/filings/0001193125-25-266077.md) | [1,832](/filings/0001193125-26-334178.md) | [1,820](/filings/0001193125-26-213510.md) | [1,846](/filings/0001193125-26-334178.md) |
| Current liabilities | $m | [344](/filings/0000950170-23-060765.md) | [372](/filings/0000950170-25-022803.md) | [365](/filings/0000950170-24-057487.md) | [333](/filings/0000950170-24-092351.md) | [373](/filings/0000950170-24-121901.md) | [371](/filings/0001193125-26-056502.md) | [358](/filings/0000950170-25-067608.md) | [337](/filings/0000950170-25-103628.md) | [356](/filings/0001193125-25-266077.md) | [360](/filings/0001193125-26-334178.md) | [335](/filings/0001193125-26-213510.md) | [368](/filings/0001193125-26-334178.md) |
| Total liabilities | $m | [491](/filings/0000950170-23-060765.md) | [558](/filings/0000950170-25-022803.md) | [547](/filings/0000950170-24-057487.md) | [504](/filings/0000950170-24-092351.md) | [550](/filings/0000950170-24-121901.md) | [519](/filings/0001193125-26-056502.md) | [509](/filings/0000950170-25-067608.md) | [505](/filings/0000950170-25-103628.md) | [497](/filings/0001193125-25-266077.md) | [500](/filings/0001193125-26-334178.md) | [468](/filings/0001193125-26-213510.md) | [495](/filings/0001193125-26-334178.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [1,125](/filings/0000950170-23-060765.md) | [1,147](/filings/0000950170-25-022803.md) | [1,184](/filings/0000950170-24-057487.md) | [1,193](/filings/0000950170-24-092351.md) | [1,243](/filings/0000950170-24-121901.md) | [1,211](/filings/0001193125-26-056502.md) | [1,260](/filings/0000950170-25-067608.md) | [1,295](/filings/0000950170-25-103628.md) | [1,297](/filings/0001193125-25-266077.md) | [1,326](/filings/0001193125-26-334178.md) | [1,345](/filings/0001193125-26-213510.md) | [1,343](/filings/0001193125-26-334178.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [58.1 d](/filings/0000950170-24-121901.md) | [72.4 d](/filings/0001193125-26-056502.md) | [80.6](/filings/0000950170-25-067608.md) | [4.7 d](/filings/0000950170-25-103628.md) | [73.5 d](/filings/0001193125-25-266077.md) | [25.7 d](/filings/0001193125-26-056502.md) | [28.3](/filings/0001193125-26-213510.md) | [10.5 d](/filings/0001193125-26-334178.md) | [38.1 d](/filings/0001193125-25-266077.md) | [61.4 d](/filings/0001193125-26-056502.md) | [17.6](/filings/0001193125-26-213510.md) | [7.2 d](/filings/0001193125-26-334178.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $m | [0.0 d](/filings/0000950170-24-121901.md) | [17.9 d](/filings/0001193125-26-056502.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-266077.md) | [19.8 d](/filings/0001193125-26-056502.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-266077.md) | [21.6 d](/filings/0001193125-26-056502.md) | not reported | not reported |
| Share repurchases | $m | [0.0 d](/filings/0000950170-24-121901.md) | [0.1 d](/filings/0001193125-26-056502.md) | [0.4](/filings/0000950170-25-067608.md) | [0.3 d](/filings/0000950170-25-103628.md) | [0.0 d](/filings/0001193125-25-266077.md) | [0.0 d](/filings/0001193125-26-056502.md) | [4.8](/filings/0001193125-26-213510.md) | [8.5 d](/filings/0001193125-26-334178.md) | [10.6 d](/filings/0001193125-25-266077.md) | [0.0 d](/filings/0001193125-26-056502.md) | [7.1](/filings/0001193125-26-213510.md) | [6.4 d](/filings/0001193125-26-334178.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [25.0](/filings/0000950170-23-060765.md) | [25.0](/filings/0000950170-24-057487.md) | [25.0](/filings/0000950170-24-092351.md) | [25.0](/filings/0000950170-24-121901.md) | [25.1](/filings/0000950170-25-067608.md) | [25.1](/filings/0000950170-25-103628.md) | [25.1](/filings/0001193125-25-266077.md) | [25.1](/filings/0001193125-26-213510.md) | [25.0](/filings/0001193125-26-334178.md) | [24.9](/filings/0001193125-25-266077.md) | [24.8](/filings/0001193125-26-213510.md) | [24.7](/filings/0001193125-26-334178.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 24,631,047 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-334178.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.